<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751848/" ref="ordinalpos=2153&amp;ncbi_uid=5268802&amp;link_uid=PMC3751848" image-link="/pmc/articles/PMC3751848/figure/pone-0074420-g002/" class="imagepopup">Figure 2. Metformin activates AMPK, Akt, and UPR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> proteins in ALL primary and cell line models..  From: Metformin Induces Apoptosis through AMPK-Dependent Inhibition of UPR <span class="highlight" style="background-color:">Signaling</span> in ALL Lymphoblasts. </a></div><br /><div class="p4l_captionBody"><b>A</b>) Western blot analysis of proteins associated with AMPK, and Akt/mTOR signaling pathways in CCRF-CEM and NALM6 cells treated with metformin (MET, 2.5 and 5.0 mM) for 48 h. The density value of each band was normalized to β-actin level and expressed relative to control (shown as fold induction). <b>B</b>) Immunoblotting of UPR signaling factors in CCRF-CEM and NALM6 cells treated with metformin (MET, 2.5 and 5.0 mM) for 48 h. <b>C</b>) Western blots of AMPK, Akt/mTOR and UPR signaling proteins in representative sample of primary T- and Bp-ALL cells treated with metformin (MET, 10 mM) for 24 h. <b>D</b>) Western blot analysis of GRP78 expression in CCRF-CEM and NALM6 cells treated with metformin (MET, 10mM) and tunicamycin (TUN, 2.5 µg/ml for NALM6; 5.0 µg/ml for CCRF-CEM), either alone or in combination for 48 h.</div></div>